HYLO®

EvoTears®

EvoTears®: Unique1 in the treatment of dry eyes caused by a lipid phase disorder

What is a lipid phase disorder?

In almost 60 % of cases, dry eyes are exclusively caused by a lipid phase disorder2, i.e. an unstable or deficient lipid or oil phase of the tear film. This phase marks the outermost layer of the tear film forming a boundary to the environment. Its task is to counteract premature evaporation of the tear and to stabilise the aqueous phase of the tear film.

A lipid phase disorder results in an increased evaporation of the underlying aqueous phase and thus dry eyes. However, due to the destabilisation of the aqueous phase, watery eyes can also occur.

Innovation for dry eyes

Since 2015, EvoTears® eye drops have represented an unprecedented therapeutic class for the treatment of dry eyes. The first anhydrous drops for the treatment of dry eyes specifically address the lipid phase disorder, which is the sole cause of the clinical picture in almost 60 % of those affected1. This leads to premature evaporation of the tear film and thus to dry eyes. In addition, EvoTears® are the first eye drops with the innovative active ingredient perfluorohexyloctane. Thanks to perfluorhexyloctane, the EvoTears® eye drops spread quickly and lie like a protective layer over the tears. This prevents excessive evaporation and effectively relieves the discomfort of dry eyes. Because EvoTears® are anhydrous, they contain no additives. Tear substitutes are used as a basic therapy for dry eyes, while purely moisturising eye drops have no direct effect on an existing lipid phase disorder.
With EvoTears®, an unprecedented class of therapy for the treatment of dry eyes due to a lipid phase disorder has been available since 2015. EvoTears®, the unique2 lipid replacement, convinces with its effect and tolerability and is suitable for the majority of patients with dry eyes.

Typical symptoms associated with a lipid phase disorder are 

  • Watery eyes
  • Burning sensation
  • Symptoms predominately in the morning and improving throughout the day

Causes of a lipid phase disorder are e.g.

  • Use of digital media
  • Current of air or air conditioning
  • Office Eye Syndrome
  • Unfavourable climatic influences/conditions

Tear substitutes are used as a basic treatment for dry eyes, whereby purely hydrating eye drops have no direct influence on an existing lipid phase disorder.

With EvoTears® an unprecedented therapeutic class in the treatment of dry eyes has been available since 2015.

EvoTears® – Unique1 lipid replacement for dry eyes

  • Innovative, lipophilic, water-free – Made in Germany 
  • Takes over the function of the lipid phase by forming a protective layer over the tear 
  • Effective protection against evaporation for satisfied patients 
  • No need for additives

EvoTears® stands for …

1. Perfluorohexyloctane

EvoTears® is lipophilic, thanks to the innovative substance perfluorohexyloctane, and yet has the same refractive index as the tear. Thus, vision is not impaired. 

Perfluorohexyloctane has other advantageous properties that have not been known to date in the treatment of dry eyes. EvoTears® spreads very quickly and rapidly forms a protective layer over the tear to counteract premature evaporation. In addition, a drop has a volume of only about 10 μl and therefore up to 280 drops per 3 ml content can be dispensed from one bottle of EvoTears®.

2. Being water-free

EvoTears® are the first water-free drops in the treatment of dry eyes, as they contain only the substance perfluorohexyloctane. Thus EvoTears® does not require any additives such as preservatives, phosphates or emulsifiers.

EvoTears® are the first water-free eye drops in the treatment of dry eyes. The effective protection against evaporation generates satisfied patients.

Use of EvoTears®

Due to its low surface tension EvoTears® may exit from the bottle without applying pressure.

 

EvoTears® Pharmacode Shelf life after opening Storage
3 ml eye drops 6603627 6 months Not above 25 °C


1 due to perfluorohexyloctane and being water-free
2 Tong L et al. Invest Ophthalmol Vis Sci, 2010. 51: 3449-3454.

PDF download link

Pack shot (printable version)